Skip to main content

Table 1 Baseline characteristics of selected 2241 pairs with locoregionally advanced nasopharyngeal carcinoma

From: Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma

Characteristics

CCRT (n = 2241)

IC + CCRT (n = 2241)

P value

No. (%)

No. (%)

 

Gender

  

0.838a

 Male

585 (26.1)

579 (25.8)

 

 Female

1656 (73.9)

1662 (74.2)

 

Age (years)

  

0.791b

 Median (range)

44 (18–77)

45 (18–76)

 

Smoking

  

0.828a

 Yes

819 (36.5)

812 (36.2)

 

 No

1422 (63.5)

1429 (63.8)

 

Drinking

  

0.703a

 Yes

321 (14.3)

330 (14.7)

 

 No

1920 (85.7)

1911 (85.3)

 

Family History of cancer

  

0.606a

 Yes

572 (25.5)

557 (24.9)

 

 No

1669 (74.5)

1684 (75.1)

 

T category c

  

0.208a

 T1

107 (4.8)

136 (6.0)

 

 T2

179 (8.0)

176 (7.9)

 

 T3

1461 (65.2)

1416 (63.2)

 

 T4

494 (22.0)

513 (22.9)

 

N category c

  

0.03a

 N0

186 (8.3)

188 (8.4)

 

 N1

1151 (51.4)

1138 (50.8)

 

 N2

635 (28.3)

699 (31.2)

 

 N3

269 (12.0)

216 (9.6)

 

Overall stage c

  

0.501a

 III

1516 (67.6)

1537 (68.6)

 

 IVA-B

725 (32.4)

704 (31.4)

 

LDH (U/L)

  

0.204b

 Median (range)

174 (67–1009)

176 (39–753)

 

EBV-DNA (copies/ml)

 

0.141b

 Median (range)

6345 (0–13,100,000)

4610 (0–9,080,000)

 
  1. Abbreviations: NPC nasopharyngeal carcinoma, CCRT concurrent chemoradiotherapy, IC induction chemotherapy, LDH lactate dehydrogenase, EBV-DNA Epstein-Barr virus DNA
  2. aP values were calculated by Chi-square test
  3. bP values were calculated by t test
  4. cAccording to the 8th edition of UICC/AJCC staging system